

Kenneth R Chapman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3592157/publications.pdf>

Version: 2024-02-01

154
papers

9,318
citations

47006

47
h-index

39675

94
g-index

154
all docs

154
docs citations

154
times ranked

7689
citing authors

#	ARTICLE	IF	CITATIONS
1	Indacaterolâ€“Glycopyrronium versus Salmeterolâ€“Fluticasone for COPD. <i>New England Journal of Medicine</i> , 2016, 374, 2222-2234.	27.0	688
2	Epidemiology and costs of chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , 2006, 27, 188-207.	6.7	606
3	Tiotropium in Combination with Placebo, Salmeterol, or Fluticasoneâ€“Salmeterol for Treatment of Chronic Obstructive Pulmonary Disease. <i>Annals of Internal Medicine</i> , 2007, 146, 545.	3.9	590
4	Intravenous augmentation treatment and lung density in severe α 1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2015, 386, 360-368.	13.7	408
5	Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. <i>Lancet Respiratory Medicine</i> , the, 2016, 4, 781-796.	10.7	398
6	Minimal Clinically Important Differences in Pharmacological Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 250-255.	5.6	360
7	Gender Bias in the Diagnosis of COPD. <i>Chest</i> , 2001, 119, 1691-1695.	0.8	319
8	Suboptimal asthma control: prevalence, detection and consequences in general practice. <i>European Respiratory Journal</i> , 2008, 31, 320-325.	6.7	293
9	Adverse effects of inhaled corticosteroids. <i>American Journal of Medicine</i> , 1995, 98, 196-208.	1.5	239
10	Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. <i>Lancet Respiratory Medicine</i> , the, 2013, 1, 524-533.	10.7	219
11	Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 329-339.	5.6	196
12	Effect of a Short Course of Prednisone in the Prevention of Early Relapse after the Emergency Room Treatment of Acute Asthma. <i>New England Journal of Medicine</i> , 1991, 324, 788-794.	27.0	193
13	A Cohort Study of Traffic-Related Air Pollution and Mortality in Toronto, Ontario, Canada. <i>Environmental Health Perspectives</i> , 2009, 117, 772-777.	6.0	190
14	Asthma Control in Canada Remains Suboptimal: The Reality of Asthma Control (TRAC) Study. <i>Canadian Respiratory Journal</i> , 2006, 13, 253-259.	1.6	187
15	Adult Asthma Consensus Guidelines Update 2003. <i>Canadian Respiratory Journal</i> , 2004, 11, 9A-18A.	1.6	171
16	Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. <i>Journal of Allergy and Clinical Immunology</i> , 1995, 96, 571-579.	2.9	163
17	Augmentation Therapy for α 1 Antitrypsin Deficiency: A Meta-Analysis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2009, 6, 177-184.	1.6	160
18	Long-term efficacy and safety of α 1 proteinase inhibitor treatment for emphysema caused by severe α 1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 51-60.	10.7	151

#	ARTICLE	IF	CITATIONS
19	Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1189-1197.	5.6	139
20	Physician Perceptions and Management of COPD. Chest, 1993, 104, 254-258.	0.8	126
21	Long-term Safety and Efficacy of Indacaterol, a Long-Acting \hat{I}^2 -Agonist, in Subjects With COPD. Chest, 2011, 140, 68-75.	0.8	126
22	Control of Asthma in Canada: Failure to Achieve Guideline Targets. Canadian Respiratory Journal, 2001, 8, 35A-40A.	1.6	124
23	Canadian Cohort Obstructive Lung Disease (CanCOLD): Fulfilling the Need for Longitudinal Observational Studies in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 125-132.	1.6	122
24	Undiagnosed Chronic Obstructive Pulmonary Disease Contributes to the Burden of Health Care Use. Data from the CanCOLD Study. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 285-298.	5.6	110
25	Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respiratory Medicine, the, 2022, 10, 11-25.	10.7	109
26	Maximal Inspiratory and Expiratory Pressures in Adolescents. Chest, 1984, 86, 568-572.	0.8	107
27	The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1716-1726.	5.7	106
28	Acclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and) Tj ETQq0 0 0 rBT /Overlock 10 Tf 5		
29	Once-daily, single-inhaler mometasoneâ€“indacaterolâ€“glycopyrronium versus mometasoneâ€“indacaterol or twice-daily fluticasoneâ€“salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respiratory Medicine, the, 2020, 8, 1000-1012.	10.7	98
30	Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial. BiolImpacts, 2020, 10, 209-215.	1.5	98
31	Chronic obstructive pulmonary disease: are women more susceptible than men?. Clinics in Chest Medicine, 2004, 25, 331-341.	2.1	96
32	Improving the Management of COPD in Women. Chest, 2017, 151, 686-696.	0.8	86
33	Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The ENLIGHTEN study. Respiratory Medicine, 2013, 107, 1558-1567.	2.9	82
34	Randomised controlled trial for emphysema with a selective agonist of the \hat{I}^3 -type retinoic acid receptor. European Respiratory Journal, 2012, 40, 306-312.	6.7	77
35	Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD. International Journal of COPD, 2011, 6, 353.	2.3	76
36	Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease: Figure 1:. Cmaj, 2012, 184, 1365-1371.	2.0	72

#	ARTICLE	IF	CITATIONS
37	A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. <i>BMC Pulmonary Medicine</i> , 2014, 14, 4.	2.0	70
38	Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. <i>Thorax</i> , 2010, 65, 747-752.	5.6	69
39	Asthma biomarkers in the age of biologics. <i>Allergy, Asthma and Clinical Immunology</i> , 2017, 13, 48.	2.0	68
40	Addressing Reduced Laboratory-Based Pulmonary Function Testing During a Pandemic. <i>Chest</i> , 2020, 158, 2502-2510.	0.8	63
41	Findings on Thoracic Computed Tomography Scans and Respiratory Outcomes in Persons with and without Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0166745.	2.5	63
42	Health Services Burden of Undiagnosed and Overdiagnosed COPD. <i>Chest</i> , 2018, 153, 1336-1346.	0.8	60
43	Efficacy and safety of inhaled $\hat{1}\pm$ 1-antitrypsin in patients with severe $\hat{1}\pm$ 1-antitrypsin deficiency and frequent exacerbations of COPD. <i>European Respiratory Journal</i> , 2019, 54, 1900673.	6.7	55
44	The Placebo Effect in Asthma Drug Therapy Trials: A Meta-Analysis. <i>Journal of Asthma</i> , 2000, 37, 303-318.	1.7	54
45	Physician perspectives on the burden and management of asthma in six countries: The Global Asthma Physician Survey (GAPS). <i>BMC Pulmonary Medicine</i> , 2017, 17, 153.	2.0	52
46	The Addition of Salmeterol 50 $\hat{A}\mu$ g Bid to Anticholinergic Treatment in Patients with COPD: A Randomized Placebo Controlled Trial. <i>Canadian Respiratory Journal</i> , 2002, 9, 178-185.	1.6	51
47	Relation between income, air pollution and mortality: a cohort study. <i>Cmaj</i> , 2003, 169, 397-402.	2.0	48
48	Impaired Sleep Quality in COPD Is Associated With Exacerbations. <i>Chest</i> , 2019, 156, 852-863.	0.8	47
49	$\hat{1}\pm$ 1-Antitrypsin deficiency and the risk of COVID-19: an urgent call to action. <i>Lancet Respiratory Medicine</i> , 2021, 9, 337-339.	10.7	46
50	Identification and definition of asthmaâ€™COPD overlap: The CanCOLD study. <i>Respirology</i> , 2020, 25, 836-849.	2.3	45
51	The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2017, 4, 34-44.	0.7	42
52	Prehospitalization Inhaled Corticosteroid Use in Patients With COPD or Asthma. <i>Chest</i> , 1997, 111, 296-302.	0.8	40
53	Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications. <i>International Journal of COPD</i> , 2018, Volume 13, 419-432.	2.3	37
54	Pharmacokinetic comparability of Prolastin \hat{A} [®] -C to Prolastin \hat{A} [®] in alpha1-antitrypsin deficiency: a randomized study. <i>BMC Clinical Pharmacology</i> , 2010, 10, 13.	2.5	35

#	ARTICLE	IF	CITATIONS
55	The Effect of Structured Versus Conventional Inhaler Education in Medical Housestaff. <i>Journal of Asthma</i> , 1996, 33, 385-393.	1.7	34
56	Factors associated with undiagnosed and overdiagnosed COPD. <i>European Respiratory Journal</i> , 2016, 48, 561-564.	6.7	33
57	The effects of marijuana smoking on lung function in older people. <i>European Respiratory Journal</i> , 2019, 54, 1900826.	6.7	32
58	Patient Handling of a Dry-Powder Inhaler in Clinical Practice. <i>Chest</i> , 2001, 120, 1480-1484.	0.8	31
59	The Patient Level Cost of Asthma in Adults in South Central Ontario. <i>Canadian Respiratory Journal</i> , 1998, 5, 463-471.	1.6	30
60	Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO. <i>International Journal of COPD</i> , 2021, Volume 16, 1755-1770.	2.3	30
61	Do We Know the Minimal Clinically Important Difference (MCID) for COPD Exacerbations?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013, 10, 243-249.	1.6	29
62	The relationship between omega-3 and smoking habit: a cross-sectional study. <i>Lipids in Health and Disease</i> , 2016, 15, 61.	3.0	26
63	Dual Bronchodilation Response by Exacerbation History and Eosinophilia in the FLAME Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1223-1226.	5.6	25
64	Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1693.	7.4	25
65	Effect of Inhaled Furosemide in Acute Asthma. <i>Journal of Asthma</i> , 1998, 35, 89-93.	1.7	24
66	Dynamic Airway Evaluation with Volume CT: Initial Experience. <i>Canadian Association of Radiologists Journal</i> , 2010, 61, 90-97.	2.0	24
67	Ambient Air Pollution and Dysanapsis: Associations with Lung Function and Chronic Obstructive Pulmonary Disease in the Canadian Cohort Obstructive Lung Disease Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 44-55.	5.6	24
68	Inhaler Education for Hospital-Based Pharmacists: How Much Is Required?. <i>Canadian Respiratory Journal</i> , 1999, 6, 237-244.	1.6	23
69	Quality Assurance of Spirometry in a Population-Based Study – Predictors of Good Outcome in Spirometry Testing. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2014, 11, 143-151.	1.6	23
70	Psychological distress is related to poor health behaviours in COPD and non-COPD patients: Evidence from the CanCOLD study. <i>Respiratory Medicine</i> , 2019, 146, 1-9.	2.9	22
71	Asthma patients' and physicians'™ perspectives on the burden and management of asthma. <i>Respiratory Medicine</i> , 2021, 186, 106524.	2.9	21
72	The efficacy of acclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis. <i>International Journal of COPD</i> , 2016, Volume 11, 2041-2053.	2.3	20

#	ARTICLE	IF	CITATIONS
73	Evaluation of a Questionnaire to Assess Compliance with Antiasthma Medications. <i>Journal of Asthma</i> , 2004, 41, 77-83.	1.7	19
74	Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data. <i>International Journal of COPD</i> , 2015, 10, 1599.	2.3	19
75	Impaired Ventilatory Efficiency, Dyspnea, and Exercise Intolerance in Chronic Obstructive Pulmonary Disease: Results from the CanCOLD Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1391-1402.	5.6	19
76	Tiotropium and Simplified Detection of Dynamic Hyperinflation. <i>Chest</i> , 2007, 131, 690-695.	0.8	18
77	Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics. <i>Respiratory Research</i> , 2021, 22, 144.	3.6	18
78	A Randomized Controlled Trial to Determine the Effect of Inhaled Corticosteroid on Intraocular Pressure in Open-Angle Glaucoma and Ocular Hypertension: The ICOUGH Study. <i>Journal of Glaucoma</i> , 2017, 26, 182-186.	1.6	17
79	The Role of Omalizumab in the Treatment of Severe Allergic Asthma. <i>Canadian Respiratory Journal</i> , 2006, 13, 1B-9B.	1.6	16
80	Alpha-1 Antitrypsin Deficiency in Canada: Regional Disparities in Diagnosis and Management. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015, 12, 15-21.	1.6	16
81	Assessing biomarkers in a real-world severe asthma study (ARIETTA). <i>Respiratory Medicine</i> , 2016, 115, 7-12.	2.9	16
82	The Prevalence of Chronic Obstructive Pulmonary Disease (COPD) and the Heterogeneity of Risk Factors in the Canadian Population: Results from the Canadian Obstructive Lung Disease (COLD) Study. <i>International Journal of COPD</i> , 2021, Volume 16, 305-320.	2.3	16
83	Self-Management and Clinical Decision Support for Patients With Complex Chronic Conditions Through the Use of Smartphone-Based Telemonitoring: Randomized Controlled Trial Protocol. <i>JMIR Research Protocols</i> , 2017, 6, e229.	1.0	16
84	Bronchodilator Responsiveness and Reported Respiratory Symptoms in an Adult Population. <i>PLoS ONE</i> , 2013, 8, e58932.	2.5	14
85	Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study. <i>International Journal of COPD</i> , 2018, Volume 13, 1125-1134.	2.3	14
86	Tracheobronchial dilation during isocapnic hypoxia in conscious humans. <i>Journal of Applied Physiology</i> , 1993, 75, 1728-1733.	2.5	13
87	Asthma Education: The United Kingdom Experience. <i>Chest</i> , 1994, 106, 216S-218S.	0.8	12
88	Real-life effectiveness of indacaterol–glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study. <i>International Journal of COPD</i> , 2019, Volume 14, 249-260.	2.3	12
89	Triaging Access to Critical Care Resources in Patients With Chronic Respiratory Diseases in the Event of a Major COVID-19 Surge. <i>Chest</i> , 2020, 158, 2270-2274.	0.8	12
90	Seretide for obstructive lung disease. <i>Expert Opinion on Pharmacotherapy</i> , 2002, 3, 341-350.	1.8	11

#	ARTICLE	IF	CITATIONS
91	Women and Asthma: Lessons from a Gender Analysis of the Asthma in Canada Survey. <i>Journal of Asthma</i> , 2006, 43, 169-173.	1.7	11
92	The COPD Assessment Test. <i>Chest</i> , 2016, 150, 1069-1079.	0.8	11
93	Reality-Based Medicine. <i>Chest</i> , 2000, 118, 281-283.	0.8	10
94	Economic Issues in the Use of Office Spirometry for Lung Health Assessment. <i>Canadian Respiratory Journal</i> , 2003, 10, 320-326.	1.6	10
95	Comparative efficacy of indacaterol in chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2012, 7, 145.	2.3	10
96	Safety of biweekly α_1 -antitrypsin treatment in the RAPID programme. <i>European Respiratory Journal</i> , 2018, 52, 1800897.	6.7	10
97	The impact of budesonide and other inhaled corticosteroid therapies in the management of asthma in children and adults. <i>Clinical Therapeutics</i> , 2003, 25, C2-C14.	2.5	9
98	Impact of pulmonary nontuberculous mycobacterial treatment on pulmonary function tests in patients with and without established obstructive lung disease. <i>Respirology</i> , 2015, 20, 987-993.	2.3	9
99	Work productivity loss in mild to moderate COPD: lessons learned from the CanCOLD study. <i>European Respiratory Journal</i> , 2017, 50, 1701154.	6.7	9
100	Quantitative disease progression model of α_1 proteinase inhibitor therapy on computed tomography lung density in patients with α_1 antitrypsin deficiency. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2386-2397.	2.4	9
101	Overall and Cardiovascular Safety of Acclidinium Bromide in Patients With COPD: A Pooled Analysis of Six Phase III, Placebo-Controlled, Randomized Studies. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2017, 2017, 784314.	0.7	7
102	Omalizumab for asthma: pharmacology and clinical profile. <i>Expert Review of Respiratory Medicine</i> , 2009, 3, 119-127.	2.5	7
103	The clinical impact of single inhaler therapy in asthma. <i>Clinical and Experimental Allergy</i> , 2012, 42, 1006-1013.	2.9	7
104	Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD. <i>Pulmonary Therapy</i> , 2019, 5, 23-41.	2.2	7
105	Dyspnoea and symptom burden in mild to moderate COPD: the Canadian Cohort Obstructive Lung Disease Study. <i>ERJ Open Research</i> , 2021, 7, 00960-2020.	2.6	7
106	QVA149 Improves Lung Function, Dyspnea, and Health Status Independent of Previously Prescribed Medications and COPD Severity: A Subgroup Analysis from the SHINE and ILLUMINATE Studies. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2014, 2, 48-60.	0.7	7
107	Long-Term Evaluation of the Effects of Acclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2018, 5, 5-15.	0.7	7
108	The Choice of Inhalers in Adults and Children over Six. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 1995, 8, S-27-S-36.	1.2	6

#	ARTICLE	IF	CITATIONS
109	Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 43-51.	5.6	6
110	Difficult Asthma: Consider All of the Possibilities. <i>Canadian Respiratory Journal</i> , 2000, 7, 415-418.	1.6	5
111	Safer Inhaled Corticosteroid Therapy for Asthma. <i>Pediatrics</i> , 2008, 121, 179-180.	2.1	5
112	Asthma in Canada: missing the treatment targets. <i>Cmaj</i> , 2008, 178, 1027-1028.	2.0	5
113	Asthma that is unresponsive to usual care. <i>Cmaj</i> , 2010, 182, 45-52.	2.0	5
114	Mortality among Subjects with Chronic Obstructive Pulmonary Disease or Asthma at Two Respiratory Disease Clinics in Ontario. <i>Canadian Respiratory Journal</i> , 2011, 18, 327-332.	1.6	5
115	SMART isn't. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 609-610.	2.9	4
116	Acidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661985072.	2.6	4
117	Dysanapsis and the Spirometric Response to Inhaled Bronchodilators. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 997-1001.	5.6	4
118	One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000819.	3.0	4
119	The prevalence of asthma and atopy in schoolchildren from Porto Alegre, Brazil, has plateaued. <i>Respiratory Medicine</i> , 2015, 109, 308-311.	2.9	3
120	Bench to Bedside and Back: The Evolving Story of Alpha-1 Antitrypsin Deficiency. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020, 63, 403-404.	2.9	3
121	Position statement from the Canadian Thoracic Society (CTS) on clinical triage thresholds in respiratory disease patients in the event of a major surge during the COVID-19 pandemic. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 214-225.	0.5	3
122	Acidinium bromide/formoterol fumarate as a treatment for COPD: an update. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1093-1106.	2.5	3
123	Reply: What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 1230-1231.	5.6	2
124	The Hidden Story of Nonadherence with Asthma Therapy: For a Few Dollars More?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2307-2308.	3.8	2
125	Association of Obstructive Apnea with Thoracic Fluid Shift and Small Airways Narrowing in Asthma During Sleep. <i>Nature and Science of Sleep</i> , 2022, Volume 14, 891-899.	2.7	2
126	Letter to the Editor Response. COPD: <i>Journal of Chronic Obstructive Pulmonary Disease</i> , 2010, 7, 235-236.	1.6	1

#	ARTICLE	IF	CITATIONS
127	The Arietta Study: Exploring Severe Asthma Biomarkers in a Real-World Setting. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB256.	2.9	1
128	Current thinking and new paradigm for COPD. <i>Respiratory Medicine</i> , 2016, 112, 126-127.	2.9	1
129	Reply to Lan and Shi: Different Background, Short Duration, and Inappropriate Participants May Harm Your Conclusion. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 390-392.	5.6	1
130	Targeted management of severe asthma: Developing a Canadian approach. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 124-132.	0.5	1
131	Chronic Obstructive Pulmonary Disease: Is Social Injustice the Elephant in the Room?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1331-1332.	5.6	1
132	Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma. <i>Clinical Drug Investigation</i> , 2021, 41, 489-492.	2.2	1
133	Effect of indacaterol/glycopyrronium (IND/GLY) vs salmeterol/fluticasone (SFC) on moderate or severe COPD exacerbations and lung function based on baseline blood eosinophil counts: Results from the FLAME study. , 2016, , .		1
134	Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers. <i>Respiratory Research</i> , 2021, 22, 272.	3.6	1
135	Increased proportion of slow decliners in patients with alpha-1 protease inhibitor (A1-PI) deficiency following treatment with A1-PI. , 2016, , .		1
136	Safety of bi-weekly intravenous therapy with alpha-1 antitrypsin. , 2017, , .		1
137	Alpha-1 antitrypsin (A1-PI) treatment slows emphysema progression independent of baseline FEV1. , 2017, , .		1
138	Trust but Verify. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4288-4289.	3.8	1
139	Le R�le de lâ™Omalizumab dans le Traitement de lâ™Asthme Allergique Grave. <i>Canadian Respiratory Journal</i> , 2006, 13, 10B-20B.	1.6	0
140	A Step Forward in COPD Management. <i>Chest</i> , 2012, 142, 1082-1085.	0.8	0
141	Exacerbations in non-COPD patients: truth or myth? authorsâ™ response. <i>Thorax</i> , 2014, 69, 1050.2-1051.	5.6	0
142	Reply to Cooper et al.: The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 968-969.	5.6	0
143	Improving Asthma Management: A Tale of Two Countries. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1926.	3.8	0
144	Anticholinergic Bronchodilator Therapy of Asthmaâ™Ageless. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2661-2662.	3.8	0

#	ARTICLE	IF	CITATIONS
145	The Impact of Exacerbation History on the Safety and Efficacy of Acclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial. International Journal of COPD, 2021, Volume 16, 689-699.	2.3	0
146	Efficacy of Acclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial. Advances in Therapy, 2021, 38, 5381-5397.	2.9	0
147	Just as the Twig Is Bent, the Tree's Inclined. Annals of the American Thoracic Society, 2021, 18, 1461-1463.	3.2	0
148	Are Women More Susceptible to Chronic Obstructive Pulmonary Disease?. , 2010, , 252-259.		0
149	Correlation between change in lung density and lung function parameters in treated alpha-1 protease inhibitor (A1-PI) deficiency. , 2016, , .		0
150	Indacaterol/glycopyrronium (IND/GLY) improves lung function, health status and rescue medication use vs salmeterol/fluticasone (SFC) independent of symptom response: The FLAME study. , 2017, , .		0
151	Indacaterol/glycopyrronium (IND/GLY) reduces days with COPD exacerbation vs salmeterol/fluticasone (SFC) independent of PRO tool: results of the FLAME study. , 2017, , .		0
152	Delayed time to first and subsequent exacerbations independent of season with indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone (SFC): the FLAME study. , 2017, , .		0
153	If All That You Have Is a Hammer: Can We Phenotype Our Patients with Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 266-267.	5.6	0
154	Primary Care Severe Asthma Registry and Education Project (PCSAR-EDU): Phase 1 " an e-Delphi for registry definitions and indices of clinician behaviour. BMJ Open, 2022, 12, e055958.	1.9	0